Pinnacle Associates’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$925K Buy
21,182
+4,469
+27% +$207K 0.01% 548
2026
Q2
$713K Buy
16,713
+2,720
+19% +$148K 0.01% 607
2026
Q1
$878K Buy
13,993
+6,232
+80% +$499K 0.01% 541
2025
Q4
$740K Sell
7,761
-12
-0.2% -$1.18K 0.01% 576
2025
Q3
$759K Sell
7,773
-315
-4% -$32.6K 0.01% 556
2025
Q2
$869K Buy
8,088
+404
+5% +$40.9K 0.01% 535
2025
Q1
$775K Sell
7,684
-232
-3% -$23.4K 0.01% 530
2024
Q4
$707K Buy
7,916
+586
+8% +$51.6K 0.01% 536
2024
Q3
$424K Sell
7,330
-438
-6% -$34.5K 0.01% 603
2024
Q2
$598K Buy
7,768
+290
+4% +$21.2K 0.01% 550
2024
Q1
$512K Buy
7,478
+148
+2% +$9.5K 0.01% 581
2023
Q4
$424K Buy
7,330
+77
+1% +$4.11K 0.01% 611
2023
Q3
$383K Sell
7,253
-179
-2% -$9.39K 0.01% 612
2023
Q2
$402K Buy
7,432
+343
+5% +$17.9K 0.01% 611
2023
Q1
$355K Buy
7,089
+287
+4% +$13.5K 0.01% 589
2022
Q4
$315K Buy
6,802
+1,189
+21% +$51.5K 0.01% 593
2022
Q3
$217K Buy
+5,613
New +$225K 0.01% 677

Other funds holding BSX

Pinnacle Associates's BSX Position: Q3 2026 in Review

Pinnacle Associates increased its Boston Scientific (BSX) stake by 27% in Q3 2026, buying an estimated $207K and bringing the position to 21,182 shares worth $925K. The position accounts for 0.01% of the portfolio, ranked #548.

Pinnacle Associates first reported a position in BSX in Q3 2022 and has held it in 17 quarters since. 545 funds tracked by Wall St. Rank hold BSX as of Q3 2026.

  • Pinnacle Associates held 21,182 shares of Boston Scientific worth $925K as of Q3 2026.
  • Pinnacle Associates bought 4,469 Boston Scientific shares in Q3 2026, an estimated $207K.
  • Boston Scientific made up 0.01% of Pinnacle Associates's portfolio in Q3 2026, its #548 holding.
  • Pinnacle Associates first reported a position in Boston Scientific in Q3 2022 and has held it in 17 quarters since.
  • 545 funds tracked by Wall St. Rank held Boston Scientific as of Q3 2026.

Based on Pinnacle Associates's 13F filing for Q3 2026, filed 20 Oct 2026.